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Considering the feasibility, tolerability and safety of high intensity interval training as a 




Peripheral arterial disease (PAD) is characterised by atherosclerosis of the arteries supplying 
the lower limbs, resulting in a reduced blood supply1 and is estimated to affect 237 million 
people globally2. The most common symptom of PAD is intermittent claudication (IC), 
characterised by reproducible ischaemic muscle pain in the leg, precipitated by exertion and 
relieved by rest3-6. IC has deleterious effects on walking ability, functional capacity and quality 
of life (QoL), whilst also carrying a markedly increased mortality risk3,4,7-9. First line 
management of IC includes a supervised exercise programme (SEP)10,11. Interval walking is 
the recommended exercise component of SEP, though improvements are also obtainable with 
other modalities, including stationary cycling12,13. Cycle testing is also better tolerated than 
treadmill testing in IC patients, whilst inducing greater cardiometabolic responses, likely 
because patients may prematurely terminate treadmill testing due to claudication pain, 
precluding them from reaching higher intensities14. 
The evidence for the clinical efficacy of SEP, irrespective of exercise modality, is irrefutable12. 
Despite this, less than half of vascular units in the UK have access to them15, and recruitment 
rates are often as low as 25%16. Patients cite time and SEP duration as reasons for inability to 
attend17.  
In addition, SEP exercise prescription usually adopts ‘a one size fits all’ approach based on a 
subjective measure of claudication pain, potentially limiting its benefit. High-intensity interval 
training (HIIT) is a more time-efficient, personally prescribed exercise intervention based on 
  
objectively measured cardiorespiratory fitness via cardiopulmonary exercise testing (CPX). It 
therefore has the potential to maximise individual benefit and overcome the aforementioned 
patient cited barriers. HIIT has demonstrated similar or superior physiological benefits 
compared to lower intensity programmes across both healthy and clinical populations18-24, and 
may be the preferred intensity option for IC patients17. A recent systematic review has provided 
initial, limited evidence that HIIT may be beneficial for IC patients whilst recommending 
further studies of low-volume, short-term HIIT25. However, such HIIT interventions remain 
largely untested in those with IC. Therefore, in line with the Medical Research Council 
guidance, a feasibility study is required to develop and test the intervention to identify problems 
with acceptability, compliance, delivery, recruitment and retention that can be addressed prior 
to larger-scale evaluation26. Therefore, the aim of this study was to assess a novel HIIT 






This prospective, interventional, before-after cohort study was conducted at a tertiary vascular 
centre in the United Kingdom and registered on clinicaltrials.gov (NCT04042311). Approval 
was obtained via a local NHS research ethics committee and all patients provided informed 
consent. 
PARTICIPANTS 
Patients with IC referred for our conventional SEP were screened for study participation. 
Patients were eligible if they were aged >18 yr, English speaking and able to follow exercise 
  
instructions and provide informed consent, walk unaided and had a resting ankle-brachial 
pressure index (ABPI) <0.90 or a reduction of ≥20mmHg in systolic pressure, measured at the 
ankle following treadmill testing. Those who had critical limb-threatening ischaemia (rest 
pain/tissue loss), were undergoing active cancer treatment, had inadequately controlled 
cardiometabolic diseases, or elicited any contraindications to exercise testing or training were 
excluded27. Patients meeting these criteria who were willing to participate were invited to 
attend a baseline assessment which included a CPX. Following this, patients were also 
excluded if they elicited significant exercise-induced myocardial ischaemia or were unable to 
achieve maximal effort test criteria (supplementary table),28,29 as this is required for accurate 
and effective ‘traditional’ HIIT exercise prescription. However, following a review of the 
inclusion/exclusion criteria due to a completion rate that was lower than anticipated for the first 
20 patients, this maximal effort criterion was removed and no longer applied to the final 10 
patients that make up the 30 patients in this cohort. 
 
OUTCOMES 
The primary aims of this study were to assess the, feasibility, tolerability and safety of short-
term, low-volume HIIT for IC. Potential efficacy was also considered. 
Feasibility assessment included; eligibility, recruitment and completion rates. 
Tolerability assessment included; reasons for withdrawal (i.e. whether they were related to the 
intervention) and the ability of patients to achieve and maintain exercise in the appropriate 
exercise intensity domain.  
Safety assessment included; adverse event (AE) reporting related to the intervention/outcome 
measures. 
  
Indicators of clinical efficacy assessment included; initial claudication (ICD) and maximal 
walking distance (MWD), ABPI, QoL and cardiorespiratory fitness measurements. These 
measures were assessed at baseline and immediately following the HIIT programme.  
 
PROCEDURES 
ABPI was recorded at rest using standardised methods11, followed by a graded treadmill 
walking test, with a constant speed of 3.2km/h and incremental gradient starting at 0% and 
increasing by 2% every two min, for a maximum of 15 min30. Those unable to walk at 3.2km/h 
were permitted to walk at a slower speed, selected by the assessor, which was kept consistent 
at follow-up to ensure standardisation.  
ICD and MWD was recorded as the distance which patients first reported claudication pain and 
the distance at which pain became too severe and they needed to stop. Post-exercise ABPI was 
then recorded. 
 
Quality of Life 
QoL was measured using the Medical Outcomes Study Short-Form 36 v.2 (SF-36) and the 
King’s College Hospitals Vascular QoL (VascuQoL) questionnaires31,32. Both questionnaires 
have several domains with the SF-36 also producing component summary scores and the 
VascuQoL producing a total score. 
 
Cardiorespiratory fitness 
All patients performed a symptom-limited ramp incremental cycle ergometer (Lode Corival 
Serial) CPX. Breath-by-breath gas exchange data were collected using a metabolic cart 
  
(Ultima2, Medgraphics), calibrated to manufacturers’ instructions prior to each test. Heart rate 
and rhythm was monitored continuously via 12-lead ECG (Mortara X-scribe, Mortara). 
Oxygen saturation and blood pressure (Tango M2 system, SunTech Medical) were assessed 
periodically throughout the test. 
Each CPX was preceded by a 3-minute rest period and a 3-minute unloaded phase prior to a 
patient-specific ramp protocol of 10, 15, or 20 Watts per minute, designed to induce volitional 
exhaustion within 8-12 min33. Patients were instructed to maintain 60-70 revolutions per 
minute and in the absence of clinical indications for stopping27, were encouraged to exercise 
until volitional exhaustion. The Borg 6 to 20 rating of perceived exertion (RPE) scale was used 
to quantify subjective effort. The requirement to give a maximal effort was explained 
thoroughly and strong verbal encouragement was given throughout. Expired ventilatory gases 
were continuously collected during the rest and exercise periods and for at least 6 min into 
recovery34.  
Peak oxygen uptake was defined as the highest value achieved during the last 30s of exercise 
or early in recovery. The ventilatory anaerobic threshold was determined using the V-slope and 
ventilatory equivalents methods35,36.  
 
Intervention 
The HIIT intervention was based on an ongoing randomised controlled trial in patients with 
coronary artery disease28, and consisted of 6 wk of supervised, intermittent cycling 3 d per wk, 
prescribed on the basis of the baseline CPX. Patients completed 10 x 1-minute high-intensity 
intervals (set at 85-90% peak power output, to achieve ≥85% peak heart rate by the second 
interval) interspersed with 1-minute recovery intervals on a Wattbike Trainer, to achieve a total 
of 20 min exercise time. Patients were permitted to complete less than 10 intervals, progressing 
  
up to 10 bouts on an individual basis. The variation in intensity was achieved by altering 
cycling cadence and patients were continuously monitored via a Polar heart rate monitor (FT2, 
Polar electro) and RPE37, with both recorded at the end of each high-intensity interval. Each 
session was preceded and followed by a 10-minute warm-up and cool-down as is recommended 
for patients with cardiovascular disease38. 
 
Data analysis 
The primary aims of this study were to consider the, feasibility, tolerability and safety of a 
novel HIIT programme. Therefore, descriptive rather than statistical analysis was performed. 
Data is presented as mean/mean difference ± SD. Due to the nature of this study and analysis, 




Baseline characteristics of all recruited patients (n = 30) are shown in table 1. Mean age was 
69±9 yr, body mass index was 29±4 kg/m2, and 77% were male. The mean ABPI was 
0.75±0.21. Exercise programme completers and non-completers were similar in baseline 
characteristics.  
 
Feasibility and Tolerability 
Between April 2018 and July 2019, 144 patients with IC were referred for SEP of whom 95 
were eligible (66%) and 30 consented to participate in supervised HIIT (32%).  
 
Of the initial 20 patients recruited, seven were excluded from further participation; two had 
abnormal ECG changes and five could not meet the criteria for a maximal effort CPX. The 
  
peak respiratory-exchange-ratio and percentage of age-predicted maximum heart rate (%) in 
the patient’s excluded and those meeting maximal exercise test criteria were 0.9 and 1.1 and 
72% and 83% respectively (table 2). Of the remaining thirteen patients eligible and able to 
commence the HIIT programme, one withdrew due to an inability to tolerate the intervention, 
two withdrew due to developing a concurrent illness and one moved out of the area. One 
participant withdrew due to an AE probably related to the exercise intervention.  
Thereafter, eight of these twenty (40%) patients completed the HIIT programme. 
 
Following a review of the inclusion/exclusion criteria and to improve pragmatism it was 
decided that patients would no longer be excluded on the basis of an inability to achieve a 
maximal effort CPX. Once this exercise testing entry criterion was removed, a further ten 
patients were recruited of which seven (70%) completed the programme. One patient was 
excluded due to ischaemic ECG changes, and another withdrew due to reported time 
constraints. One further withdrawal was due to a serious adverse event (SAE) that was possibly 
related to the intervention.   
Of this second cohort of ten patients, two (20%) were unable to achieve a maximal effort CPX, 
comparable to the 25% in the initial cohort. Of these, one completed the programme and is 
included in the analysis. The full study processes are outlined in Figure 1.  
Overall, fifteen (50%) of the thirty patients recruited in the total cohort completed the 
programme and attended eighteen sessions, for a 100% adherence rate, over an average of 
6.5±0.8 wk. ≥85% peak heart rate was achieved by the second interval in 79% of sessions. All 
ten intervals were completed in 87% of sessions, with 14 of the 15 patients able to complete 





There was one AE and one SAE possibly related to the intervention. The AE was a first, 
isolated episode of a ‘dull chest ache’ that occurred in the period between two exercise sessions. 
Following referral to cardiology a diagnosis of probable angina was made but not confirmed 
as diagnostic angiogram was refused.  
The SAE was a thrombosed popliteal aneurysm that occurred in the period between two 
exercise sessions. The patient was admitted for surgery and underwent a lower limb bypass 
procedure. Whilst it is possible that this was related to the intervention, the first symptomatic 
manifestation (acute limb ischemia) occurred two d after the last exercise session, meaning that 
it was not definitively attributable to the exercise intervention. 
No AEs occurred during or immediately following any HIIT exercise sessions or study visits. 
 
Efficacy 
Improvements were noted in a number of efficacy measures including ICD, MWD, PPO and 




The eligibility (66%) and recruitment (32%) rates for this HIIT programme were similar to 
those previously reported for standard SEP16. Completion rates, although lower than reported 
within the literature16, were comparable to the rates for the usual-care SEP provided in our 
centre and likely reflective of “real-world” exercise programmes39. However, for the first 20 
patients, given the post-recruitment CPX exclusion criterion, it is likely that the 
inclusion/exclusion criteria were not comparable to SEPs. For the final 10 patients, for whom 
the inclusion/exclusion criteria were likely comparable to those applied within SEPs, the 
  
completion rate was similar to that reported in the literature and higher than the usual-care SEP 
in our centre16,39. This suggests that HIIT may be a feasible alternative to traditional SEP for 
claudication and implementation of it was relatively straightforward. The patient withdrawal 
rate (20%) in this study was somewhat higher than HIIT programmes in other clinical 
populations40,41. However, this may be due to the small sample in this cohort, the close attention 
given to recording patient referrals, recruitment/withdrawals which may not be comparable 
within other reports and some older age and comorbidity profile characteristics of PAD cohorts. 
Further, the present withdrawal rate was similar to SEP16, and the majority of sessions were 
completed in full and at the required intensity, suggesting that HIIT is no less tolerable than 
current practice.  
There was one SAE possibly related to the intervention, though it did not require any changes 
to the study procedures. The AE rate was higher in this HIIT group (2/30) than has been noted 
in our SEP (1/109), though a larger group of HIIT patients is required for direct 
comparison39.No AEs occurred during or immediately following any HIIT sessions or study 
visits. Accordingly, this study provides an early indication that HIIT may be safe in IC patients, 
though further evidence is required, including direct comparison to a SEP group. However, 
these early safety findings may be confounded by the use of a baseline CPX, which may help 
to screen out those at higher risk of a cardiac event during HIIT. Current evidence suggests that 
CPX prior to SEP is not necessary42, as the number of patients screened out is low (3.5%). 
Furthermore, the AE rate is approximated to be one in every 10,340 patient-hr42. It would be 
reasonable to assume that the relative intensity of SEP is lower than that for HIIT and therefore 
may be less likely to elicit an adverse cardiac response. Furthermore, a large proportion of PAD 
patients have co-existing coronary artery disease43, and a number of these will be undiagnosed. 
Indeed, 10% of patients were excluded following a positive baseline CPX in this study. One 
later had confirmed triple vessel disease and underwent quadruple coronary artery bypass 
  
grafting, whilst another required permanent pacemaker insertion. The potential cardiac risks 
presented by HIIT in IC patients remains largely undefined and further evidence is needed from 
a larger cohort of patients. Certainly, any exercise programme adopting HIIT should undertake 
a baseline CPX (with exercise ECG screening) to ensure accurate exercise prescription and 
patient safety.  
 
One salient finding of this study is that several patients were excluded as they were unable to 
achieve a maximal effort CPX, precluding prescription of a ‘traditional’ HIIT programme. This 
inability to achieve a maximal test is likely to be due to severe deconditioning of patients with 
IC due a cycle of pain and physical activity avoidance5. The mean baseline peak oxygen uptake 
for the patients in this study was higher than previously reported in those with IC at 
approximately 15 mL∙kg-1∙min-139,44, but lower than reported in recent HIIT studies in those 
with coronary artery disease (23 mL∙kg-1∙min-1) and heart failure (17 mL∙kg-1∙min-1)40,41. This 
suggests that IC patients terminate exercise prematurely due to a perception of fatigue and/or 
are markedly more deconditioned than those with chronic and advanced heart disease. This 
may explain why a number of patients were unable to achieve a maximal effort CPX, despite 
subjectively feeling they have performed to their limit. Indeed, the patients unable to achieve 
a maximal effort test in this cohort reported a mean RPE score of >18/20. 
However, those who are most deconditioned, have the potential to accrue the most benefit from 
participating in supervised, structured exercise following a personalised HIIT prescription. 
Indeed, the ventilatory anaerobic threshold, a submaximal marker of cardiorespiratory fitness 
has been demonstrated to be a significant predictor of improvement in walking distance 
following SEP, with the least fit having the greatest improvement in walking distance39.  
Based on the proportion of patients who were excluded due to an inability to achieve a maximal 
CPX, we altered the inclusion/exclusion criteria and conducted further feasibility work. This 
  
‘submaximal’ version of the short-term HIIT programme did not exclude patients on the basis 
of an inability to achieve a maximal CPX. Instead patients received the same personalised, 
time-efficient programme prescribed on the basis of their baseline submaximal CPX. The 
rationale for this alteration was two-fold. Firstly, the patients excluded on this criterion, may 
have the potential to achieve the largest clinical benefits. Secondly, despite a similar 
withdrawal rate, the completion rate for the first 20 patients was just 40%. Once the maximal 
exercise test criterion was removed in the secondary cohort, the completion rate improved to 
70%.  
 
Those who completed HIIT, had improvements in walking distance and QoL. Our small sample 
and study design, however, precludes statistical comparison and substantive evidence of 
clinical benefits. Despite this, the results show promise given the improvements in MWD in 
this sample, were comparable to SEP (122m vs. 117m) and represent a large minimally 
clinically important change, provided in half the usual programme duration39,45.  
Therefore, HIIT programmes for IC patients appear to have the potential to provide clinical 
and symptomatic improvements. As the intervention period is reduced from twelve to six wk, 
with potentially comparable outcomes, it can reduce patient burden and may be easier to 
deliver. This may therefore provide a cost reduction at both patient and provision level. Finally, 
this exercise prescription moves away from a ‘one size fits all’ approach and adopts a 
personalised exercise prescription based on a CPX, with the ability to maximise patient benefit, 
which has also been recommended for cardiovascular rehabilitation programmes, both in the 




One key limitation of this study is that participants were recruited from patients referred to a 
usual-care SEP. It is therefore not possible to identify if patients who chose to take part in this 
study are simply those who would have also chosen to take part in SEP. Also, patients who 
chose to take part in HIIT rather than SEP, may have been more motivated to do so, meaning 
the results may not be reflective of the overall population.The small sample size precluding 
statistical analysis, the single-centre design and the lack of a comparison group are also 
limitations of this study. However, this feasibility work is vital to ensure the intervention and 
inclusion criteria are appropriate, or whether they need to be altered, as in this case, to inform 




This study has provided preliminary findings to suggest that patients with IC can perform HIIT, 
with uptake and completion rates similar to standard SEP. It has also provided an early 
indication that with relevant pre-screening HIIT may be safe for patients with IC. It is also well 
tolerated and potentially efficacious. Following a small change, the intervention and 
inclusion/exclusion criteria now appear appropriate for this population. A larger, proof-of-
concept study appears warranted prior to randomised controlled trials of HIIT versus usual SEP 
in patients with IC.   
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 Figure Legend: Figure 1: Participant flow chart 
